Investors Seek Lead in Gossamer Bio Securities Fraud Lawsuit

Schall Law Firm announces opportunity for investors to lead class action against biotech firm.

Apr. 3, 2026 at 4:53pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a collection of polished, geometric objects in shades of gray and blue on a clean, monochromatic background, conceptually representing the complex financial and regulatory landscape facing biotech companies.A minimalist studio still life captures the abstract challenges facing biotech firms navigating financial and regulatory scrutiny.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, has announced that investors in Gossamer Bio, Inc. have the opportunity to lead a class action lawsuit against the biotech company over allegations of securities fraud. The lawsuit alleges that Gossamer Bio made false and misleading statements about the development and prospects of its lead drug candidate.

Why it matters

Shareholder lawsuits against public companies over alleged securities fraud are common, but can have significant financial and reputational impacts if the claims are found to have merit. This case highlights the ongoing scrutiny biotech firms face from investors regarding the progress and transparency of their drug development pipelines.

The details

The Schall Law Firm is investigating claims on behalf of investors that Gossamer Bio made false and misleading statements about the development of its lead drug candidate, GB001, for the treatment of chronic rhinosinusitis. The lawsuit alleges that Gossamer misled investors about the drug's efficacy and the likelihood of it receiving regulatory approval.

  • The lawsuit was announced on April 3, 2026.

The players

The Schall Law Firm

A national shareholder rights litigation firm that is investigating claims against Gossamer Bio on behalf of investors.

Gossamer Bio, Inc.

A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of respiratory diseases.

Got photos? Submit your photos here. ›

What’s next

The Schall Law Firm is encouraging Gossamer Bio investors to contact the firm to discuss the opportunity to serve as lead plaintiff in the securities fraud lawsuit.

The takeaway

This lawsuit underscores the importance of biotech companies providing transparent and accurate information to investors about the progress and prospects of their drug development pipelines. Shareholders will be closely watching the outcome of this case and its potential impact on Gossamer Bio.